Adoptive cell therapies are showing promise as innovative ways of treating patients with cancer. Chimeric antigen receptor (CAR) T-cell therapy is currently paving the way for adoptive cell therapies in treatment of hematological malignancies and solid tumors including melanoma, breast cancer and sarcoma.
Developing such a therapeutic presents substantial challenges including:
The imaging team at DICE can assist in the process of theragnostic development (radiation dosimetry, phantom harmonization), development and selection of novel metabolic and molecular tumor microenvironment-specific radiotracers.
Due to the complexity of metabolic and molecular imaging in the context of novel CAR-T or other genetically engineered therapies, we are in close collaboration with a medical physicist highly skilled in the fields of nanotechnology, radiation therapy, and molecular imaging.